Directrices internacionales

Reino Unido

Rheumatoid arthritis in adults: management

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2020

Biologic DMARD safety guidelines in inflammatory arthritis

Publicado por:The British Society for Rheumatology

Publicado por última vez:2019

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2019

Baricitinib for moderate to severe rheumatoid arthritis

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2017

Sarilumab for moderate to severe rheumatoid arthritis

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2017

Prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs

Publicado por:British Society for Rheumatology; British Health Professionals in Rheumatology Standards

Publicado por última vez:2017

Tofacitinib for moderate to severe rheumatoid arthritis

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2017

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2016

Tocilizumab for the treatment of rheumatoid arthritis

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2012

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2010

Total wrist replacement

Publicado por:National Institute for Health and Care Excellence

Publicado por última vez:2008

Europa

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Publicado por:European League Against Rheumatism

Publicado por última vez:2022

ESMO management of toxicities from immunotherapy

Publicado por:European Society for Medical Oncology

Publicado por última vez:2022

EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis

Publicado por:European League Against Rheumatism

Publicado por última vez:2021

EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

Publicado por:European League Against Rheumatism

Publicado por última vez:2021

Clinical practice guidelines for rheumatoid arthritis: from the Italian Society for Rheumatology

Publicado por:Italian Society for Rheumatology

Publicado por última vez:2019

Management of patients with rheumatoid arthritis

Publicado por:Spanish Society of Rheumatology

Publicado por última vez:2019

2016 update of the EULAR recommendations for the management of early arthritis

Publicado por:European League Against Rheumatism

Publicado por última vez:2016

EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis

Publicado por:European League Against Rheumatism

Publicado por última vez:2013

América del Norte

2023 American College of Rheumatology (ACR) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic disease

Publicado por:American College of Rheumatology; American College of Chest Physicians

Publicado por última vez:2023

2023 American College of Rheumatology (ACR) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic disease

Publicado por:American College of Rheumatology; American College of Chest Physicians

Publicado por última vez:2023

Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases

Publicado por:American College of Rheumatology

Publicado por última vez:2023

Guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis

Publicado por:American College of Rheumatology

Publicado por última vez:2022

Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying antirheumatic drugs

Publicado por:Canadian Rheumatology Association

Publicado por última vez:2022

ACR appropriateness criteria: chronic extremity joint pain - suspected inflammatory arthritis

Publicado por:American College of Radiology

Publicado por última vez:2022

American College of Rheumatology guideline for the treatment of rheumatoid arthritis

Publicado por:American College of Rheumatology

Publicado por última vez:2021

Oceanía

Australian living guideline for the pharmacological management of inflammatory arthritis

Publicado por:Australian Rheumatology Association

Publicado por última vez:2024

Asia

The use of methotrexate in patients with rheumatoid arthritis

Publicado por:Japan College of Rheumatology

Publicado por última vez:2023

APLAR recommendations for treatment of rheumatoid arthritis

Publicado por:Asia Pacific League of Associations for Rheumatology

Publicado por última vez:2019

Management of rheumatoid arthritis: from the Hong Kong Society of Rheumatology

Publicado por:Hong Kong Society of Rheumatology

Publicado por última vez:2019

Management of rheumatoid arthritis

Publicado por:Published by: Hong Kong Society of Rheumatology

Publicado por última vez:2019

Latinoamérica

2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis

Publicado por:Brazilian Society of Rheumatology

Publicado por última vez:2021

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad